Market Place
Sourcing Support
All News #Library
Others
Q32 Bio names Adrien Sipos, M.D., Ph.D., Interim CMO
25 Jun 2025 //
PR NEWSWIRE
FDA Fast Track Designation for Bempikibart for Alopecia Areata
30 Apr 2025 //
PR NEWSWIRE
Q32 Bio Completes Enrollment In Phase 2 Bempikibart Dermatitis Trial
09 Jul 2024 //
PR NEWSWIRE
Q32 Bio Joins Russell 3000® Index Logo
01 Jul 2024 //
PR NEWSWIRE
Q32 Bio Q1 2024 Financials, Corporate Update
09 May 2024 //
PR NEWSWIRE
Q32 Bio Announces Closing of Merger with Homology & Placement of $42M
25 Mar 2024 //
PR NEWSWIRE
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy
21 Feb 2024 //
PR NEWSWIRE
Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer
24 Oct 2023 //
PR NEWSWIRE
Q32 Bio and Horizon Announce Dosing of First Patient in Phase 2 Trial of ADX-914
27 Oct 2022 //
PRESS RELEASE
Q32 Bio Announces CEO Transition
20 Sep 2022 //
PRNEWSWIRE
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
15 Aug 2022 //
PRNEWSWIRE
Q32 Bio Presents New Preclinical Data at ISNF for ADX-097
23 Jun 2022 //
PRNEWSWIRE
Q32 Bio Initiates First-in-Human PI Study of ADX-097
26 May 2022 //
PRNEWSWIRE
Q32 Bio to Present Preclinical Data on Next Generation Complement ADX-097
18 Oct 2021 //
PRNEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.